NKG2C+ NK cells are enriched in AIDS patients with advanced-stage Kaposi's sarcoma

Journal of Virology

Volumn 81, Issue 1, 2007, Pages 430-433

  Goodier, Martin R ^a   Mela, C M ^a   Steel, A ^a   Gazzard, B ^a   Bower, M ^a   Gotch, F ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P46;

ADULT; AGED; AIDS PATIENT; ARTICLE; CELL FUNCTION; CELL LINE; CELL TYPE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; KIR3DL1 GENE; MALE; NATURAL KILLER CELL; NATURAL KILLER CELL NKG2C; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; STAGING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMANS; KILLER CELLS, NATURAL; NEOPLASM STAGING; PHENOTYPE; RECEPTORS, IMMUNOLOGIC; SARCOMA, KAPOSI;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33845792422     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01567-06     Document Type: Article

References (23)

1. Ahmad, R., S. T. Sindhu, P. Tran, E. Toma, R. Morisset, J. Menezes, and A. Ahmad. 2001. Modulation of expression of the MHC class I-binding natural killer cell receptors, and NK activity in relation to viral load in HIV-infected/AIDS patients. J. Med. Virol. 65:431-440.
2. Alter, G., J. M. Malenfant, and M. Altfeld. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294:15-22.
3. Bottino, C., L. Moretta, D. Pende, M. Vitale, and A. Moretta. 2004. Learning how to discriminate between friends and enemies, a lesson from natural killer cells. Mol. Immunol. 41:569-575.
4. Deayton, J. R., C. A. Sabin, M. A. Johnson, V. C. Emery, P. Wilson, and P. D. Griffiths. 2004. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 363:2116-2121.
5. De Maria, A., M. Fogli, P. Costa, G. Murdaca, F. Puppo, D. Mavilio, A. Moretta, and L. Moretta. 2003. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30, and NKp44). Eur. J. Immunol. 33:2410-2418.
6. Fauci, A. S., D. Mavilio, and S. Kottilil. 2005. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5:835-843.
7. Goodier, M. R., N. Imami, G. Moyle, B. Gazzard, and F. Gotch. 2003. Loss of the CD56hiCD16-NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone. Clin. Exp. Immunol. 134:470-476.
8. Gumá, M., A. Angulo, C. Vilches, N. Gomez-Lozano, N. Malats, and M. Lopez-Botet. 2004. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104:3664-3671.
9. Gumá, M., M. Budt, A. Saez, T. Brckalo, H. Hengel, A. Angulo, and M. Lopez-Botet. 2006. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 107:3624-3631.
10. Gumá, M., L. K. Busch, L. I. Salazar-Fontana, B. Bellosillo, C. Morte, P. Garcia, and M. Lopez-Botet. 2005. The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells. Eur. J. Immunol. 35:2071-2080.
11. Gumá, M., C. Cabrera, I. Erkizia, M. Bofill, B. Clotet, L. Ruiz, and M. Lopez-Botet. 2006. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J. Infect. Dis. 194:38-41.
12. Hoare, H. L., L. C. Sullivan, G. Pietra, C. S. Clements, E. J. Lee, L. K. Ely, T. Beddoe, M. Falco, L. Kjer-Nielsen, H. H. Reid, J. McCluskey, L. Moretta, J. Rossjohn, and A. G. Brooks. 2006. Structural basis for a major histocompatibility complex class Ib-restricted T cell response. Nat. Immunol. 7:256-264.
13. Krown, S. E., M. A. Testa, and J. Huang. 1997. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J. Clin. Oncol. 15:3085-3092.
14. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23:225-274.
15. López-Vózquez, A., A. Mina-Blanco, J. Martinez-Borra, P. D. Njobvu, B. Suarez-Alvarez, M. A. Blanco-Gelaz, S. Gonzalez, L. Rodrigo, and C. Lopez-Larrea. 2005. Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population. Hum. Immunol. 66:285-289.
16. Martin, M. P., X. Gao, J. H. Lee, G. W. Nelson, R. Detels, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, J. Trowsdale, M. Wilson, S. J. O'Brien, and M. Carrington. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31:429-434.
17. Mavilio, D., J. Benjamin, M. Daucher, G. Lombardo, S. Kottilil, M. A. Planta, E. Marcenaro, C. Bottino, L. Moretta, A. Moretta, and A. S. Fauci. 2003. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. USA 100:15011-15016.
18. + natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc. Natl. Acad. Sci. USA 102:2886-2891.
19. Meier, U. C., R. E. Owen, E. Taylor, A. Worth, N. Naoumov, C. Willberg, K. Tang, P. Newton, P. Pellegrino, I. Williams, P. Klenerman, and P. Borrow. 2005. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J. Virol. 79:12365-12374.
20. Mela, C. M., C. T. Burton, N. Imami, M. Nelson, A. Steel, B. G. Gazzard, F. M. Gotch, and M. R. Goodier. 2005. Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS 19:1761-1769.
21. Robain, M., F. Boufassa, J. B. Hubert, A. Persoz, M. Burgard, and L. Meyer. 2001. Cytomegalovirus seroconversion as a cofactor for progression to AIDS. AIDS 15:251-256.
22. Sirianni, M. C., L. Vincenzi, S. Topino, A. Giovannetti, F. Mazzetta, F. Libi, D. Scaramuzzi, M. Andreoni, E. Pinter, S. Baccarini, G. Rezza, P. Monini, and B. Ensoli. 2002. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur. J. Immunol. 32:2711-2720.
23. Stebbing, J., B. Gazzard, O. Flore, C. Thomas, A. Benlahrech, S. Mandalia, M. Bower, F. Gotch, and S. Patterson. 2003. Natural killer cells are not infected by Kaposi's sarcoma-associated herpesvirus in vivo, and natural killer cell counts do not correlate with the risk of developing Kaposi's sarcoma. AIDS 17:1998-2000.